Leerink Partners Downgrades Imprivata (IMPR) to Market Perform; Doesn't See Cerner (CERN) Making Competing Bid

Leerink Partners downgraded Imprivata (NYSE: IMPR) from Outperform to Market Perform after the company agreed to be acquired by Thoma Bravo for $19.25/share.

Analyst David Larsen commented, "While Cerner (NASDAQ: CERN) (OP) could have been a good fit, we do not believe that Cerner will make a competing offer because it is highly focused on the integration of Siemens Health Services, and there seems to be greater attention on the development of CERN's population health management solution and data analytics capabilities."

For an analyst ratings summary and ratings history on Imprivata click here. For more ratings news on Imprivata click here.

Shares of Imprivata closed at $14.50 yesterday.

You May Also Be Interested In

• Citi Upgrades Sirius XM Radio (SIRI) to Neutral, 'risk-reward is balanced at prevailing levels'
• Summit Insights Downgrades Silicon Labs (SLAB) to Hold, 'expect its stock to be an inline performer'
• Citi Downgrades Molson Coors (TAP) to Sell, 'Cycling 2023 Could Be a Mountain Too Hard to Climb'